KLK3 and Familial prostate cancer: Hence, using doubled PSA values from 6 months onwards in 5ARI-treated men, and establishing a new baseline PSA level, preserves the clinical utility of the PSA test in prostate cancer detection irrespective of PSA level (52,53).